| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Over the last 12 months, insiders at Agenus Inc. have bought $0 and sold $0 worth of Agenus Inc. stock.
On average, over the past 5 years, insiders at Agenus Inc. have bought $343,050 and sold $724,322 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $324,050 was made by ARMEN GARO H (See Remarks) on 2024‑02‑15.
| 2024-02-15 | ARMEN GARO H | See Remarks | 500,000 0.0915% | $0.65 | $324,050 | -58.14% | ||
| 2023-11-15 | WIINBERG ULF | director | 25,000 0.0067% | $0.76 | $19,000 | -20.64% | ||
| 2022-01-06 | Sale | O'Day Steven J | Chief Medical Officer | 38,679 0.0149% | $3.06 | $118,346 | -16.94% | |
| 2021-09-13 | Sale | ARMEN GARO H | Chairman and CEO | 82,107 0.0357% | $6.50 | $533,696 | -56.93% | |
| 2021-09-10 | Sale | KLASKIN CHRISTINE M | PFO & PAO | 11,120 0.0047% | $6.50 | $72,280 | -57.69% | |
| 2020-06-17 | Sale | INCYTE CORP | 10 percent owner | 283,840 0.1709% | $3.66 | $1.04M | +4.04% | |
| 2020-06-16 | Sale | INCYTE CORP | 10 percent owner | 144,160 0.0877% | $3.66 | $528,015 | +4.63% | |
| 2020-06-15 | Sale | INCYTE CORP | 10 percent owner | 384,025 0.2247% | $3.57 | $1.37M | +3.05% | |
| 2020-06-12 | Sale | INCYTE CORP | 10 percent owner | 9,100 0.0055% | $3.58 | $32,556 | +6.30% | |
| 2020-06-11 | Sale | INCYTE CORP | 10 percent owner | 183,875 0.1139% | $3.77 | $692,786 | +3.20% | |
| 2017-12-12 | Sale | Valentine Karen | Chief Legal Officer | 16,716 0.0174% | $3.46 | $57,842 | -16.91% | |
| 2017-12-12 | Sale | KLASKIN CHRISTINE M | VP, Finance | 11,220 0.0117% | $3.46 | $38,836 | -16.91% | |
| 2017-12-12 | Sale | Baysal Ozer | Chief Commercial Officer | 7,424 0.0077% | $3.46 | $25,691 | -16.91% | |
| 2017-12-12 | Sale | Buell Jennifer | Chief Communications Officer | 7,022 0.0073% | $3.46 | $24,304 | -16.91% | |
| 2017-12-12 | Sale | Duncan Alex | Chief Technology Officer | 13,092 0.0137% | $3.46 | $45,302 | -16.91% | |
| 2017-10-30 | ARMEN GARO H | Chairman & CEO | 80,776 0.0835% | $3.61 | $291,706 | -2.11% | ||
| 2017-10-27 | ARMEN GARO H | Chairman & CEO | 119,224 0.1159% | $3.51 | $418,524 | -5.18% | ||
| 2017-04-12 | ARMEN GARO H | Chairman & CEO | 58,912 0.0604% | $3.29 | $194,109 | +18.52% | ||
| 2017-04-10 | ARMEN GARO H | Chairman & CEO | 141,088 0.1464% | $3.37 | $474,930 | +16.21% | ||
| 2017-02-14 | INCYTE CORP | 10 percent owner | 20M 29.1662% | $6.00 | $120M | -14.32% |
| INCYTE CORP | 10 percent owner | 16972968 61.9072% | $75.87M | 1 | 5 | <0.0001% |
| QVT Associates GP LLC | 10 percent owner | 6915630 25.2241% | $30.91M | 0 | 1 | |
| ARMEN GARO H | See Remarks | 625969 2.2832% | $2.8M | 26 | 6 | +13.6% |
| WIINBERG ULF | director | 124063 0.4525% | $554,561.61 | 2 | 0 | <0.0001% |
| Valentine Karen | Chief Legal Officer | 101521 0.3703% | $453,798.87 | 0 | 15 | |
| KLASKIN CHRISTINE M | PFO & PAO | 93056 0.3394% | $415,960.32 | 0 | 16 | |
| Sharp Shalini | director | 81311 0.2966% | $363,460.17 | 2 | 15 | +24.13% |
| HATSOPOULOS JOHN | director | 65000 0.2371% | $290,550.00 | 3 | 0 | +179.69% |
| O'Day Steven J | Chief Medical Officer | 61321 0.2237% | $274,104.87 | 0 | 1 | |
| Baysal Ozer | Chief Commercial Officer | 58790 0.2144% | $262,791.30 | 1 | 1 | +35.69% |
| Wentworth Kerry | VP, Clinical, Reg & Qual | 57410 0.2094% | $256,622.70 | 0 | 16 | |
| Buell Jennifer | Chief Communications Officer | 35656 0.1301% | $159,382.32 | 0 | 1 | |
| Duncan Alex | Chief Technology Officer | 21026 0.0767% | $93,986.22 | 0 | 1 | |
| MARGARET EISEN | director | 20000 0.0729% | $89,400.00 | 2 | 0 | +21.26% |
| Ballantyne Charles Evan | Chief Financial Officer | 10000 0.0365% | $44,700.00 | 1 | 0 | <0.0001% |
| Wright Timothy | director | 10000 0.0365% | $44,700.00 | 1 | 0 | <0.0001% |
| Thornton Peter | CFO & Sr. VP | 5000 0.0182% | $22,350.00 | 1 | 0 | +22.52% |
| SRIVASTAVA PRAMOD | director | 1610 0.0059% | $7,196.70 | 0 | 1 | |
| ATLEE FRANK V III | director | 0 0% | $0 | 0 | 1 | |
| AFEYAN NOUBAR | director | 0 0% | $0 | 0 | 1 | |
| Malik Shahzad | director | 0 0% | $0 | 0 | 2 |
$5,082,542 | 144 | 5.47% | $114.35M | |
$5,558,275 | 76 | -5.88% | $119.25M | |
$48,218,096 | 42 | 0.89% | $120.52M | |
$16,259,194 | 41 | 120.51% | $140.18M | |
$909,129 | 37 | 42.19% | $116.15M | |
Agenus Inc. (AGEN) | $140,938,207 | 36 | 14.75% | $122.55M |
$63,049,419 | 31 | 2.87% | $126.16M | |
$35,092,436 | 31 | 38.62% | $122.7M | |
$6,915,275 | 21 | -32.61% | $114.97M | |
$294,424,120 | 20 | 1.33% | $138.71M | |
$1,239,833 | 16 | 53.23% | $130.91M | |
$448,999,793 | 15 | -19.99% | $129.14M | |
$178,593,887 | 15 | -14.86% | $132.49M | |
$9,999,920 | 10 | -40.03% | $117.01M | |
$299,343 | 6 | -44.75% | $119.05M | |
$68,692,148 | 6 | -39.10% | $116.52M | |
$63,981 | 5 | -11.55% | $126.38M | |
$52,950 | 3 | 0.77% | $114.55M | |
$20,020,000 | 1 | -75.24% | $125.77M |
| Increased Positions | 40 | +39.22% | 2M | +31.72% |
| Decreased Positions | 40 | -39.22% | 887,022 | -11.55% |
| New Positions | 19 | New | 1M | New |
| Sold Out Positions | 15 | Sold Out | 490,042 | Sold Out |
| Total Postitions | 102 | 0% | 9M | +20.17% |
| Vanguard Group Inc | $7,491.00 | 9.64% | 2.41M | +115,789 | +5.05% | 2024-12-31 |
| Blackrock, Inc. | $5,451.00 | 7.01% | 1.75M | +102,832 | +6.23% | 2025-03-31 |
| B. Riley Financial, Inc. | $2,354.00 | 3.03% | 756,956 | +756,956 | New | 2024-12-31 |
| State Street Corp | $1,514.00 | 1.95% | 486,719 | +18,948 | +4.05% | 2024-12-31 |
| Geode Capital Management, Llc | $1,479.00 | 1.9% | 475,586 | -7,473 | -1.55% | 2024-12-31 |
| Morgan Stanley | $1,237.00 | 1.59% | 397,736 | +121,323 | +43.89% | 2024-12-31 |
| Gilead Sciences, Inc. | $720.00 | 0.93% | 231,663 | +231,663 | New | 2024-12-31 |
| Northern Trust Corp | $650.00 | 0.84% | 208,933 | +26,870 | +14.76% | 2024-12-31 |
| Goldman Sachs Group Inc | $423.00 | 0.54% | 135,934 | +54,160 | +66.23% | 2024-12-31 |
| Susquehanna International Group, Llp | $402.00 | 0.52% | 129,162 | +32,978 | +34.29% | 2024-12-31 |